McNicoll, Lewis & Vlak maintained its SuperGen SUPG Buy rating and $8 price target after SuperGen's acquisition announcement of Astex Therapeutics in a research report published today.
In the report, MLV states, "We expect SuperGen to provide an update on corporate structure and realignment plans of the new entity during the upcoming 2Q:11 earnings call (date still to be determined). Pending these announcements, MLV is maintaining its BUY recommendation and one-year target price of $8.00 for SuperGen, Inc."
Shares of SuperGen closed today at $2.94, up 0.34% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in